Congress has sent President Biden two bills to boost generic and biosimilar drugs. Generics are exact copies and biosimilars are highly similar to original brand products. | Shutterstock

Congress Passes Bills Aimed at Boosting Generics and Biosimilars

The U.S. House of Representatives passed two bills last week intended to reduce the overall costs of medications by boosting competition for generic drugs and biosimilars. As both bills were previously passed by the Senate, they are headed to President Joe Biden’s desk for his signature.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content